Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Seattle Genetics (SGEN) PT Raised to $100 at Cowen
October 30, 2019 7:45 AM EDTCowen analyst Boris peaker raised the price target on Seattle Genetics (NASDAQ: SGEN) to $100.00 (from $80.00) while maintaining a Market Perform rating.... More
H.C. Wainwright Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:44 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
Seattle Genetics (SGEN) PT Lowered to $107 at RBC Capital
October 30, 2019 6:31 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $107.00 (from $109.00) while maintaining a Outperform rating.... More
Seattle Genetics (SGEN) Misses Q3 EPS by 19c, Revenues Beat; Raises FY19 Revenue Outlook
October 29, 2019 4:14 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
